Crotedumab

Crotedumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetGCGR
Clinical data
Other namesREGN1193
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6518H10044N1732O2052S46
Molar mass146976.88 g·mol−1

Crotedumab (REGN1193) (INN) is a humanized monoclonal antibody designed for the treatment of diabetes.[1][2]

This drug was developed by Regeneron Pharmaceuticals.

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Crotedumab, American Medical Association.
  2. ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.